University Of Tasmania
Browse

File(s) under permanent embargo

COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement

journal contribution
posted on 2023-05-21, 02:51 authored by McCaughan, G, Di Ciaccio, P, Ananda-Rajah, M, Gilroy, N, MacIntyre, R, Teh, B, Weinkove, R, Curnow, J, Szer, J, Enjeti, AK, Ross, DM, Mulligan, S, Trotman, J, Dickinson, M, Quach, H, Choi, P, Polizzotto, MN, Tam, CS, Ho, PJ, Ku, M, Gregory, G, Gangatharan, S, Hapgood, G, Cochrane, T, Cheah, C, Gibbs, S, Wei, A, Anna JohnstonAnna Johnston, Greenwood, M, Prince, HM, Latimer, M, Berkahn, L, Wight, J, Armytage, T, Hamad, N
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 vaccination in patients with haematological disorders. It is our recommendation that patients with haematological malignancies, and some benign haematological disorders, should have expedited access to high-efficacy COVID-19 vaccines, given that these patients are at high risk of morbidity and mortality from COVID-19 infection. Vaccination should not replace other public health measures in these patients, given that the effectiveness of COVID-19 vaccination, specifically in patients with haematological malignancies, is not known. Given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.

History

Publication title

Internal Medicine Journal

Volume

51

Issue

5

Pagination

763-768

ISSN

1444-0903

Department/School

Tasmanian School of Medicine

Publisher

Blackwell Publishing Asia

Place of publication

54 University St, P O Box 378, Carlton, Australia, Victoria, 3053

Rights statement

© 2021 Royal Australasian College of Physicians

Repository Status

  • Restricted

Socio-economic Objectives

Treatment of human diseases and conditions

Usage metrics

    Exports